This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated ARC Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-ARC WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~45.3 kDa | |
| Gel | 10–12% | |
| Negative control | siRNA / KO lysate |
| PTM | Phosphorylated + Ubiquitinated | |
| Caveat | Oligomerizes into capsids | |
| Regulation | LPS-induced | |
| Isoform | 1 isoform(s) |
Literature-validated Western blot parameters for ARC — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human U20S , Lane 2: human 293T , Lane 3: human SH-SY5Y , Lane 4: human SiHa , Lane 5: rat brain , Lane 6: rat C6 , Lane 7: mouse brain , Lane 8: mouse Neuro-2a . After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-Arc antigen affinity purified polyclonal antibody (Catalog # PB9753) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for Arc at approximately 45 kDa. The expected band size for Arc is at 45 kDa |
| Gel % | 10–12% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 45 kDa |
ARC has a 45.3 kDa unglycosylated monomer backbone but its expression, homooligomeric capsid state, and Ubl conjugation can add faint higher bands or weak signal outside activated neurons.
| single band near 45 kDa | matches the predicted monomer mass of ARC, consistent with no glycosylation, signal peptide, or propeptide processing |
| faint higher-molecular-weight bands or a diffuse smear above the main band | reflects a fraction of ARC retained as capsid-like homooligomers or as Ubl/isopeptide-conjugated species that resist full denaturation |
| very weak or absent band in non-neuronal or unstimulated lysates | consistent with ARC's restricted, activity-dependent expression at synapses and the postsynaptic density rather than constitutive expression |
| single sharp band with no doublet | UniProt lists only one ARC isoform, so no alternative-splicing-driven second band is expected |
| slightly shifted mobility in membrane-enriched versus cytosolic fractions | reflects the lipid-anchored (palmitoylated) membrane pool of ARC at the postsynaptic and extracellular vesicle membrane versus the unmodified cytosolic pool |
| predicted mass (45.3 kDa) | sets the baseline expected migration for monomeric, unmodified ARC |
| homooligomerization into virion-like capsids | a subpopulation can remain as higher-order oligomers that resist complete SDS/reducing denaturation, appearing as faint bands or smear above the monomer |
| ubiquitin-like (Ubl) conjugation / isopeptide bond modification | covalently modified ARC molecules run higher than the unmodified monomer, sometimes as a faint ladder |
| palmitoylation / lipid anchoring (Lipoprotein) | lipidated, membrane-associated ARC can migrate slightly differently than the unmodified cytosolic pool |
| phosphorylation at Ser260 and Thr278 | may cause a subtle upward mobility shift, though the effect is often below the resolution of standard SDS-PAGE |
| single annotated isoform | no isoform-driven extra bands are expected; additional bands should be attributed to oligomers or nonspecific binding instead |
| Situation | Likely cause | Next action |
|---|---|---|
| Weak or no signal | ARC is an activity-regulated immediate-early gene product with low basal expression outside stimulated neurons | use stimulated neuronal or brain tissue lysate as a positive control rather than resting non-neuronal cell lines |
| No band in lysate | ARC protein is rapidly turned over via ubiquitin-like conjugation and proteasomal degradation when neuronal activity is low | include proteasome inhibitors during lysis and confirm activity-dependent induction before assuming antibody failure |
| Multiple bands | incomplete dissociation of capsid-like homooligomers or a subpopulation of Ubl-conjugated ARC | boil samples longer in fresh reducing sample buffer and treat faint bands above the main band as expected minor species rather than nonspecific signal |
| Band higher than expected | residual homooligomeric capsid assemblies or isopeptide-linked Ubl conjugation not fully resolved by standard denaturation | increase reducing agent concentration and heating time, and consider fresh SDS sample buffer to improve monomer yield |
| Broad smear instead of sharp band | heterogeneous post-translational modification (phosphorylation, palmitoylation, partial oligomer breakdown) producing a range of closely spaced species | use freshly prepared lysate with phosphatase and protease inhibitors and extend gel run time to better resolve the band |
| Fragments below expected size | proteolytic or proteasomal degradation intermediates generated during ARC's normal ubiquitin-mediated turnover | include protease inhibitors, minimize freeze-thaw cycles, and process lysate quickly on ice |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for ARC, answered from its protein features.
BosterBio's ARC antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
The recommended anti-ARC antibody is a top-performing, extensively cited reagent validated through rigorous Western blot testing and cross-checked against negative tissue and complementary detection methods, ensuring specific, reproducible ARC detection for confident experimental design.
Which to pick: Only one anti-ARC antibody is catalogued, PB9753, which includes an actual Western blot validation image demonstrating specific ARC detection, making it the clear, ready-to-use choice for your ARC Western blot experiments.